Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 13;74(15):1217-22.
doi: 10.1212/WNL.0b013e3181d8c1ca. Epub 2010 Mar 10.

Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS

Affiliations

Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS

Mark L Ettenhofer et al. Neurology. .

Abstract

Background: Antiretroviral medications have been shown to benefit neurocognition in HIV/AIDS, and neurocognitive deficits are a risk factor for poor adherence to these medications. However, little is known about the predictive pathways linking medication adherence with cognitive ability.

Methods: In the current 6-month cohort study, antiretroviral medication adherence was tracked prospectively among 91 HIV-positive adults using electronic monitoring. Comprehensive neuropsychological evaluations were performed at baseline and 6 months.

Results: Multivariate path analyses provided evidence that antiretroviral adherence and cognitive ability are reciprocally related, although the neurocognitive pathways of this relationship appear to vary by predictive direction. Executive function and learning/memory were most strongly predictive of levels of medication adherence achieved, whereas higher levels of adherence were predictive of relative improvements in a wide range of frontostriatal brain functions including processing speed, attention, executive functions, and motor functioning.

Conclusions: These data provide evidence that cognition and adherence are reciprocally related in HIV/AIDS. In particular, executive dysfunction may play a key role in this relationship. Interventions aimed at improving or preserving executive functions could hold promise for interrupting progressive declines in adherence and neurocognitive ability in HIV/AIDS.

PubMed Disclaimer

Figures

None
Figure Model of longitudinal path analysis of global cognition and medication adherence N = 91; values for paths B and C represent multivariate results; *p < 0.05, **p < 0.01, †p < 0.001.

Similar articles

Cited by

References

    1. Martin EM, Pitrak DL, Novak RM, Pursell KJ, Mullane KM. Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: a preliminary report. J Clin Exp Neuropsychol 1999;21:730–735. - PubMed
    1. Suarez S, Baril L, Stankoff B, et al. Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. AIDS 2001;15:195–200. - PubMed
    1. Clerici M, Seminari E, Maggiolo F, et al. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS 2002;16:1767–1773. - PubMed
    1. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386–395. - PubMed
    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30. - PubMed

Publication types